【Exclusive】Chengdu Knowledge Vision Snares A Few Million Dollars Series A Round Led by Changrun Capital

On June 13, 2019, VCBeat learned that Chengdu Knowledge Vision has raised a few million dollars in series A round led by the subsidiary of Changrun Capital.

Founded in 2016, Knowledge Vision Technology is a company focusing on the field of medical artificial intelligence and digital pathology, committed to using machine vision, machine deep learning, and knowledge mapping and other cutting-edge artificial intelligence technologies to provide customers with accurate accompanying diagnosis, malignant tumor treatment options, and other intelligent medical services.

Knowledge Vision is committed to building an intelligent cloud platform for pathology AI application research and development. Version 1.0 of the system was first unveiled in October 2018 at the annual meeting of the pathology of China, which was unanimously recognized by the industry and peers. The platform by collecting the pathological AI auxiliary analysis of the common clinical application demand, will be involved in the pathological AI applications research and development of the technology standardization and modularization, the application research and development for pathological AI data management, image annotation, algorithm development and application of the whole process, as well as the qualitative, positioning and quantitative histological pathology and visualization, digital analysis. 

This platform fully solves the difficulties in the research and development of current pathological AI applications, high hardware investment, high pain points of communication and data labeling cost, and enables pathologists to realize the research work of pathological AI applications without large-scale coding.

Currently, Knowledge Vision mainly serves the new drug research and development, providing drug researchers with quantitative pathological analysis based on histomorphology, immunohistochemistry and in situ hybridization. By providing more accurate pathological quantitative analysis results, the system can provide intelligent decision-making assistance for drug developers, determine the correlation between pathological data characteristics and prognosis, improve the efficiency and progress of quantitative analysis of pathological sections, and ensure the consistency of histopathological analysis.

Changrun Capital aims at the commanding heights of the next generation of technology and focuses on the investment in high-end manufacturing, information technology, and the Internet. In recent years, Changrun Capital has made a deep layout in frontier science and technology fields, and successively invested in such industry benchmarking enterprises.